📄 Cross-examination of Dr. John Gerdes (afternoon, part 2) — Thursday, August 3, 1995
Address:
C:\DEPT103\CRIMINAL\1995\AUG\3\CROSS-EXAMINATION-OF-DR-JOHN-G.DOC
TRIAL
▲ Day 128 of 167

Cross-examination of Dr. John Gerdes (afternoon, part 2)

Witness: Dr. John Gerdes
Examiner: George Clarke
Called by: Defense • Date: Thursday, August 3, 1995 • Utterances: 903
Prosecutor George Clarke conducted a methodical cross-examination of defense DNA expert Dr. John Gerdes, focusing on the reliability and integrity of Gerdes' analysis of LAPD DNA laboratory contamination. Clarke successfully extracted admissions that Gerdes had renamed his central chart from 'contamination incidents' to 'unexpected alleles' because many of the flagged items may not actually be contamination, and that Gerdes had never performed forensic DNA analysis himself, had never interviewed any of the LAPD analysts, and had not reviewed the lab's polymarker results — undermining the comprehensiveness of his critique.
1 THE COURT:

All right. Thank you, ladies and gentlemen. Please be seated. Dr. Gerdes. All right. The record should reflect we have been rejoined by all the members of our jury panel. Dr. Gerdes is again on the witness stand undergoing cross-examination by Mr. Clarke. Mr. Clarke, you may continue.

2 MR. CLARKE:

Thank you, your Honor. Good afternoon again, ladies and gentlemen.

THE JURY: Good afternoon.

3 MR. CLARKE:

Dr. Gerdes, I would like to shift your attention to cross-hybridization, and in particular, with regard to cross-hybridization that can be characterized, can it not, as the appearance of additional alleles because of the closeness in sequence of one to the other? Is that a fair definition?

4 DR. GERDES:

Yes. It frequently occurs in the presence of higher levels of DNA.

5 MR. CLARKE:

You prepared a report in this matter; is that correct?

6 DR. GERDES:

I did.

7 MR. CLARKE:

And is it correct that in that report you have described the fact that additional alleles can appear weaker than alleles from the sample itself when, for instance, the temperature of this process of the typing strips showing these dots isn't correct?

8 DR. GERDES:

That's correct. If either the temperature or the salt concentration is incorrectly--the protocol is incorrectly followed, that would be an explanation--

9 MR. CLARKE:

In other words--

10 DR. GERDES:

--for weak dots.

11 MR. CLARKE:

The temperature could be off during this process and you might see a weak dot; is that right?

12 DR. GERDES:

Correct.

13 MR. CLARKE:

Or how much salt is in the solution that this development process goes on in, that could also result in a weaker dot?

14 DR. GERDES:

It might--I have to clarify that. It would result in a weaker dot on a sample from a known individual. It would not--there is no way it could result in a weak dot on a no DNA control such as the amplification blank or the reagent blank or a substrate control where there is not supposed to be any DNA in the first place. It could not result in a dot there.

15 MR. CLARKE:

In other words, when we put that chart up there of controls, if that were a reagent blank, also called a cloth control and you saw a weak signal on one of those dots, that is not from cross-hybridization, correct?

16 DR. GERDES:

No, it could not be.

17 MR. CLARKE:

But on, for instance, a known sample from a person like the positive control that we described there, that could be the subject to these additional dots showing if, for instance, the temperature were off or the salt solution were off?

18 DR. GERDES:

In that case it would be one possible explanation.

19 MR. CLARKE:

Now, as far as the differences between these alleles, and let's use DQ-Alpha, there is a 1.1 allele; is that right?

20 DR. GERDES:

Correct.

21 MR. CLARKE:

And a 1.2?

22 DR. GERDES:

Correct.

23 MR. CLARKE:

And a 1.3?

24 DR. GERDES:

Correct.

25 MR. CLARKE:

And then there are three others that are called 2, 3 and 4 are the typing strip?

26 DR. GERDES:

That's correct.

27 MR. CLARKE:

As far as the 1.1, allele it is very close in terms of its DNA sequence to the 1.2 allele; is that right?

28 DR. GERDES:

Yes.

29 MR. CLARKE:

And in fact there is only one little piece of DNA information, a base pair difference between the 1.1 and the 1.2, correct?

30 DR. GERDES:

Correct.

31 MR. CLARKE:

It is that similarity in closeness that can lead to the appearance of these additional weaker dots if a sample is, say, a 1.3 and you see a 1.1 showing up weekly?

32 DR. GERDES:

Well, specifically in the case of the 1.1, that is not really the reason that has been described for that particular allele.

33 MR. CLARKE:

Well--

34 DR. GERDES:

That particular allele is a second gene that has close sequences, the DX gene.

35 MR. CLARKE:

Okay. We will return to that. But the 1.1 and the 1.2 only differ by one base pair, correct?

36 DR. GERDES:

Correct.

37 MR. CLARKE:

And a 1.2 type can also show--simply because of this one base pair difference show some weaker reaction in the 1.1, correct?

38 DR. GERDES:

If the reaction and the protocol are correctly followed, this system is capable of detecting a one base pair difference.

39 MR. CLARKE:

All right.

40 DR. GERDES:

It is only when you have larger amounts of DNA that you have a minor percentage of that kind of cross because of the one base pair mixing.

41 MR. CLARKE:

Isn't it true--

42 DR. GERDES:

And then would you see it.

43 MR. CLARKE:

Isn't it true that this cross-hybridization due to this one base pair difference between a 1.1 and a 1.2 can appear even if large amounts of DNA are not involved?

44 DR. GERDES:

It is--the literature that I have read suggests that six nanograms and above is where the problem is.

45 MR. CLARKE:

Is it your testimony that unless there is six nanograms this cross-hybridization we know as 1.1 and a 1.2 can't happen?

46 DR. GERDES:

It is less likely to happen.

47 MR. CLARKE:

In other words, it can happen?

48 DR. GERDES:

It is possible, but it is not the more likely explanation when the DNA concentration is low.

49 MR. CLARKE:

Now, the 1.1 and the 1.3 alleles also differ by only one piece of DNA or base pair, correct?

50 DR. GERDES:

Correct.

51 MR. CLARKE:

In other words, these 1.1's, 1.2's and 1.3's are very close to one another in their sequence?

52 DR. GERDES:

Again this system is designed to detect that minor difference, one base pair in this kind of system is significant.

53 MR. CLARKE:

Objection, move to strike, nonresponsive.

54 THE COURT:

Overruled.

55 MR. CLARKE:

As far as this one base pair difference, isn't that an important piece of information for an analyst to know?

56 DR. GERDES:

Certainly. A good analyst will know the sequence of DNA he is working with.

57 MR. CLARKE:

Now, in addition to your report, the user guide talks about this very cross-hybridization, doesn't it?

58 DR. GERDES:

They talk about it in the context of specific alleles, yes.

59 MR. CLARKE:

They also describe--well, let me rephrase. The package insert that also comes with the kit also discusses this minor difference in sequence between these three subtypes of the one, correct?

60 DR. GERDES:

Between those three subtypes.

61 MR. CLARKE:

Incidentally, do you encounter any cross-hybridization in your own laboratory work?

62 DR. GERDES:

Whenever you use a dot-blot format this is a fact of life. You are going to see a certain degree of cross-hybridization.

63 MR. CLARKE:

And is that true in your laboratory's casework? I'm referring to samples that come into your laboratory you perform testing and you report results to doctors to talk about with their patients?

64 DR. GERDES:

Yes. We deal with it in a little different specific manner to accommodate that problem.

65 MR. CLARKE:

Is it also something that in your casework as an analyst performing this type of work you have to be aware of?

66 DR. GERDES:

Yes.

67 MR. CLARKE:

And is it something that from that awareness and experience you use that awareness and experience to properly interpret results?

68 DR. GERDES:

Yes. What you have to remember is in our particular case we are dealing with known single individuals. The problem becomes acute or exacerbated--

69 MR. CLARKE:

Sorry, objection, nonresponsive, your Honor.

70 THE COURT:

Sustained. Ask another question.

71 MR. CLARKE:

It is a problem and it is something you deal with in your casework, correct?

72 DR. GERDES:

This kind of problem occurs in dot-blots, yes.

73 MR. CLARKE:

Now, let's turn to this DX. In fact, what you've referred to as DX is the fact that a 1.1 allele may appear weakly, that is, weaker than the other alleles from a sample in a given case because that--because of the--I'm sorry, let me rephrase that. This DX gene phenomenon you have described is due to the fact that there is a gene close to DQ-Alpha, right?

74 DR. GERDES:

Correct.

75 MR. CLARKE:

It is not the DQ-Alpha gene?

76 DR. GERDES:

That's correct.

77 MR. CLARKE:

But it is close to it, correct?

78 DR. GERDES:

That's correct, close, not--not only in proximity, but close in terms of its sequence.

79 MR. CLARKE:

And some individuals who while they don't have the 1.1 DQ-Alpha type, may have a form of the DX gene that will weakly light up that 1.1 dot, correct?

80 DR. GERDES:

That has been described, yes.

81 MR. CLARKE:

That is described, for instance, in the user guide, correct?

82 DR. GERDES:

Correct.

83 MR. CLARKE:

That is described in the package insert?

84 DR. GERDES:

Yes.

85 MR. CLARKE:

And it is also described, isn't it, in the scientific literature?

86 DR. GERDES:

Yes.

87 MR. CLARKE:

You have recognized this DX gene, 1.1 reaction in this case by way of your report, correct?

88 DR. GERDES:

That's correct.

89 MR. CLARKE:

Now, you have described the fact that in your opinion a 1.1 reaction can only be as a result of this DX gene if the person doesn't have a 1 type at all. Do you recall that?

90 DR. GERDES:

That is not exactly the way I stated it.

91 MR. CLARKE:

Okay. Isn't it correct that there can be DX gene reaction from a person who is a type 1.1, 1.2 or 1.3?

92 DR. GERDES:

That is--that is true, but you can no longer differentiate as to whether it is true DX or if it is a true 1 type because that 1 dot is lighting up.

93 MR. CLARKE:

Okay. In a sample where the 1 allele is lighting up and let's say the person is a 1.3 and a 3, let's say, the 1 dot lights up, right?

94 DR. GERDES:

Yes.

95 MR. CLARKE:

The 1.3 dot lights up?

96 DR. GERDES:

Yes.

97 MR. CLARKE:

Actually another dot lights up because the 1.3 is there, right?

98 DR. GERDES:

Correct.

99 MR. CLARKE:

If there is a weaker 1.1, that can be from DX, can't it?

100 DR. GERDES:

It can be, but you can't tell that that in fact if that is from a contaminant or if that is from DX because in that situation you don't--you have the 1 dot lighting up, so you have no way of knowing one way or another.

101 MR. CLARKE:

What you are saying then, Dr. Gerdes, is the fact that if you see the 1.1 lighting up weakly, but the 1 dot isn't lighting up at all, you would have more confidence in concluding that that is from DX gene activity?

102 DR. GERDES:

No. I'm saying with any degree of scientific certainty you can't say one way or the other.

103 MR. CLARKE:

But in my scenario wouldn't you have more confidence that a 1.1 reaction is due to DX if you see no reaction whatsoever in the 1?

104 DR. GERDES:

Yes.

105 MR. CLARKE:

Now, I would like to turn your attention to mixtures, mixed samples.

106 DR. GERDES:

Okay.

107 MR. CLARKE:

And with regard to that, isn't it correct that with regard to mixed samples the more genetic markers you look at the more information you can obtain about a mixture?

108 DR. GERDES:

Assuming that the mixture--that's true.

109 MR. CLARKE:

In other words, if you are able to look at seven genetic markers and across all of those markers the results are consistent with a mixture of two people--

110 DR. GERDES:

Yes.

111 MR. CLARKE:

--two known people, that those seven markers give you more confidence in who that mixture came from than if you did simply a DQ-Alpha test alone?

112 DR. GERDES:

That's true.

113 MR. CLARKE:

As far as mixed samples--well, let me rephrase that. As far as contamination is concerned, isn't it true that if you use a second gene, a third gene and a fourth gene, that the likelihood of all of them being contaminated is pretty low?

114 DR. GERDES:

Again, it depends on the source of contamination. If the contamination is due to cross-contamination, that is the transfer that we talked about early on when samples are handled, that is going to be repeatedly typed, no matter how many genes you look at, as the same DNA.

115 MR. CLARKE:

Let's talk about carry-over contamination. Is what I just said to you correct?

116 DR. GERDES:

In terms--in the sense of carry-over, yes.

117 MR. CLARKE:

In other words, the more markers you look at, the more you can eliminate carry-over contamination having any impact at all or even occurring?

118 DR. GERDES:

It--that is true, but it depends on the level of background contamination in the lab at the time in terms of how much information you can get out of that approach.

119 MR. CLARKE:

Every marker you add, when the results demonstrate consistency from, say, a single person or two people, gives you more confidence that carry-over contamination didn't happen?

120 DR. GERDES:

On that specific sample, but the--the point is, if you have evidence of this kind of contamination at a high level background level in the laboratory, then that analysis falls away. I mean, it is harder to do it under those circumstances. It is sort of like if you went into your house and you noticed a cockroach and then the next day you noticed another one, it would be an indication to you that maybe there are other roaches around and you maybe better do something about it.

121 MR. CLARKE:

The cockroach comparison?

122 DR. GERDES:

I guess.

123 MR. CLARKE:

But as far as this carry-over contamination, each time do you another marker and you see consistency of results from, say, one or two persons, you are gaining more confidence as a scientist that carry-over contamination didn't happen?

124 DR. GERDES:

On that specific sample, yes.

125 MR. CLARKE:

Now, with regard to mixtures, isn't it scientifically a good idea to do additional genetic markers to get more information about that mixture?

126 DR. GERDES:

Yes.

127 MR. CLARKE:

Repeat testing also plays an important role in interpreting mixtures; is that right?

128 DR. GERDES:

Yes. Again assuming--it depends upon the stage at which the contamination occurred. If it occurs early on and is carried through a series, repeat testing isn't going to help you, but in the sense of the random events of contamination it would be helpful.

129 MR. CLARKE:

I would like to shift your attention, if I can, Dr. Gerdes, to your review of the LAPD validation strips.

130 DR. GERDES:

Okay.

131 MR. CLARKE:

Using that term generically at the moment.

132 DR. GERDES:

Yes.

133 MR. CLARKE:

You have described yesterday that from your view the Los Angeles Police Department DNA laboratory has by far the worse contamination you have seen in a forensic lab. Have I accurately described what you testified to yesterday?

134 DR. GERDES:

Yes, that's correct.

135 MR. CLARKE:

Now, the time period that you examined the Los Angeles Police Department's DNA typing results was approximately May of `93 through August of `94?

136 DR. GERDES:

Correct.

137 MR. CLARKE:

Or about a 15--15-month time period?

138 DR. GERDES:

About that, yes.

139 MR. CLARKE:

How many other laboratories have you examined all of their PCR DQ-Alpha typing strips for a 15-month time period?

KEY QUOTE
140 DR. GERDES:

For that long a period, none--no other laboratory for that long.

141 MR. CLARKE:

Have you examined any other laboratory over a twelve-month period?

142 DR. GERDES:

Umm, not twelve months, no.

143 MR. CLARKE:

I'm sorry?

144 DR. GERDES:

No.

145 MR. CLARKE:

The sample that you looked at in this case, as far as the individual strips, approximately how many was that?

146 DR. GERDES:

How many total strips?

147 MR. CLARKE:

Yes, counting every strip that you look at, and a rough estimate is fine if that would make it a little faster at this point?

148 DR. GERDES:

A little over a thousand. I think it was a 1069 or something like that.

149 MR. CLARKE:

Have you ever looked at that many strips in any other laboratory's work?

150 DR. GERDES:

No. The closest would be the Department of Justice where I looked at 203.

151 MR. CLARKE:

203 samples?

152 DR. GERDES:

Strips.

153 MR. CLARKE:

I'm sorry, strips. Over what time period?

154 DR. GERDES:

I believe theirs was over probably four to five months.

155 MR. CLARKE:

Was that a case involving again Mr. Sims?

156 DR. GERDES:

Yes.

157 MR. CLARKE:

As far as your review of the materials in this case, did you speak to Dennis Fung about his evidence collection?

158 DR. GERDES:

No.

159 MR. CLARKE:

Did you speak to Andrea Mazzola?

160 DR. GERDES:

No.

161 MR. CLARKE:

Did you speak to Greg Matheson about evidence collection in this case?

162 DR. GERDES:

No.

163 MR. CLARKE:

Did you speak to any of the employees at the LAPD laboratory about their role in this case in collecting evidence?

164 DR. GERDES:

No.

165 MR. CLARKE:

As far as your review of the strips and, we will return to the numbers in a moment, did you speak to any of the analysts asking them to help you interpret an individual strip in your review?

166 DR. GERDES:

I--Collin Yamauchi and myself sat together and I pointed out to him the things that I was observing.

167 MR. CLARKE:

Did you ask him questions about how he performed his testing as far as interpreting alleles on strips?

168 DR. GERDES:

No. I told him my interpretation and he with us present to respond and at that time he didn't.

169 MR. CLARKE:

And I'm sorry, I didn't hear the last answer?

170 DR. GERDES:

I told him my interpretation. We were sitting there together and I would say "This is a weak dot that I'm concerned about," and we go through page by page, "This is what I'm concerned about," and there was--I think he made note of those things, but I don't even know if he made official note of those, but he was certainly there at the time.

171 MR. CLARKE:

Did you ask him questions about how he interpreted things?

172 DR. GERDES:

No.

173 MR. CLARKE:

As far as any scientific test, let's use DNA typing, is it in your view important to learn how to use a test?

174 DR. GERDES:

Yes.

175 MR. CLARKE:

Is it important to gain experience in using a test?

176 DR. GERDES:

It is--yes.

177 MR. CLARKE:

Is there a training period for use of any scientific test?

178 DR. GERDES:

Yes.

179 MR. CLARKE:

Is it important to have actual physical hands-on use, hands-on work using a technique to be able to perform that technique?

180 DR. GERDES:

If you are going to perform the technique, yes, but in interpretation of scientific data, that is the nature of science. It should result in a documented piece of paper or evidence or result that can be independently analyzed by another individual who is familiar with the way--familiar with the interpretation of those results.

181 MR. CLARKE:

In your view is it important to have experience in actually using a technique to be able to interpret it, as you have done in this case?

KEY QUOTE
182 DR. GERDES:

No.

183 MR. CLARKE:

In your view then it is not important at all for you to ever have performed one of these forensic analyses?

184 DR. GERDES:

The--the interpretation of the strips are fairly straightforward. I don't feel that is necessary.

185 MR. CLARKE:

Now, as far as the LAPD's casework, when did it actually begin, in other words, accepting cases, performing DNA typing, that is PCR DQ-Alpha typing in actual cases?

186 DR. GERDES:

I believe it was--let me see if I have it here. For DQ-Alpha?

187 MR. CLARKE:

Yes.

188 DR. GERDES:

Yes.

189 MR. CLARKE:

For--

190 DR. GERDES:

For LAPD?

191 MR. CLARKE:

Yes.

192 DR. GERDES:

They began accepting cases for HLH DQ-Alpha on October 13th, 1993.

193 MR. CLARKE:

You, as a result of examining these strips that you described yesterday, created a chart; is that right?

194 DR. GERDES:

Yes.

195 MR. CLARKE:

By chart I'm referring to a document of several pages cetera in which you note a particular strip on a particular run and then a few comments about that run, correct?

196 DR. GERDES:

The--yes, the typing result that was recorded and a comment on that.

197 MR. CLARKE:

And you reviewed all of the LAPD PCR DQ-Alpha typing strips, correct?

198 DR. GERDES:

All of them they showed me.

199 MR. CLARKE:

Did you review all of the strips in their validation study?

200 DR. GERDES:

Yes.

201 MR. CLARKE:

Did you review all of the strips in their proficiency tests?

202 DR. GERDES:

Yes.

203 MR. CLARKE:

Did you review all of the strips relating to their Korean database tests?

204 DR. GERDES:

All of them they gave me. I don't think I have the entire database, but in that time frame.

205 MR. CLARKE:

Well, as far as their strips, how are they kept at their laboratory? In other words, what did you physically look at?

206 DR. GERDES:

I looked at a book very similar to what I have here, which is a run book which shows each--you know, day by day what the run and the strip looked like.

207 MR. CLARKE:

And then what would be on a page?

208 DR. GERDES:

Umm, the page has a photo of the strips and it also has the recorded typing result and the name of the analyst, the date.

209 MR. CLARKE:

And several other pieces of information?

210 DR. GERDES:

Yes. I can tell you exactly if you would like.

211 MR. CLARKE:

Well, I don't know that we need all the details, but is it correct to say for now that there is identifying information about what hybridization record it is?

212 DR. GERDES:

Yes, there is a hybridization number. There are two numbers and item number, a description of the item and then the hybridization volume, the results and also there are items about the lot numbers of specific reagents that were used to produce that result.

213 MR. CLARKE:

And I believe you described yesterday that you reviewed during this time period of May, `93, through August of `94, all of the LAPD DNA laboratory casework strips, correct?

214 DR. GERDES:

I--I'm not--I don't believe I was shown all of the casework strips, but all of them that I was shown I reviewed, yes.

215 MR. CLARKE:

Well, when you went through these books, were they--was it more than one binder?

216 DR. GERDES:

Yes, it was.

217 MR. CLARKE:

And these records have a hybridization record number, correct?

218 DR. GERDES:

Correct.

219 MR. CLARKE:

They started at what number?

220 DR. GERDES:

That I looked at?

221 MR. CLARKE:

Yes.

222 DR. GERDES:

1.

223 MR. CLARKE:

And continued through what number?

224 DR. GERDES:

261.

225 MR. CLARKE:

So if you were done looking at page 1, would you look at page 2, correct?

226 DR. GERDES:

Yes.

227 MR. CLARKE:

And so on through 261?

228 DR. GERDES:

Yes.

229 MR. CLARKE:

Did you encounter any missing numbers?

230 DR. GERDES:

There are a few, but I believe they have to do with the fact that they were polymarker runs that were incorporated in here which were given a sequence number and that wouldn't be counted as DQ-Alpha.

231 MR. CLARKE:

Okay. So from this 1 through 261 you would look at each of the pages that involved DQ-Alpha typing and if a page involved polymarker typing you didn't look at it, you would go to the next hybridization as well as--

232 DR. GERDES:

I looked at some of these as well. I didn't analyze those in as systematic a way as I did this.

233 MR. CLARKE:

So you had an opportunity to look at all the polymarker results in the LAPD laboratory as well; is that right?

234 DR. GERDES:

Yes.

235 MR. CLARKE:

You also in fact did review them?

236 DR. GERDES:

I did not have time to review those.

237 MR. CLARKE:

Did you in fact create any chart or document about polymarker results by the LAPD laboratory during this August through--May `93, through August of `94, time period?

238 DR. GERDES:

No, I didn't create a chart.

239 MR. CLARKE:

Now, as far as the term "Run," "Hybridization run," that term was used yesterday by you, correct?

240 DR. GERDES:

Yes.

241 MR. CLARKE:

What does a run mean to you?

242 DR. GERDES:

Well, the strip--each strip is one sample and a run would be all of the particular strips that were run on a given day.

243 MR. CLARKE:

In other words, the thermalcycler holds up to 96 samples, correct?

244 DR. GERDES:

Yes.

245 MR. CLARKE:

A hybridization record will only have as many as eight strips results, correct?

246 DR. GERDES:

Correct.

247 MR. CLARKE:

So a run may include one page of strips or several pages of strips; is that right?

248 DR. GERDES:

That's true.

249 MR. CLARKE:

As far as a run being in one day, what if two separate runs in the thermalcycler were done on the same day, how would you deal with that?

250 (No audible response.)
251 MR. CLARKE:

How would you count it?

252 DR. GERDES:

If it was the same date?

253 MR. CLARKE:

Yes.

254 DR. GERDES:

If it was by a different analyst, I would consider it as a different run, otherwise it would be considered as the same.

255 MR. CLARKE:

Okay. So if there is two analysts, one using the thermalcycler and then another one later using the thermalcycler, that is two runs?

256 DR. GERDES:

I went pretty much by date. One day, even if there were two people, that would still be considered one run, one day; one run.

257 MR. CLARKE:

Okay. So when, for instance, there were charts--and I believe you testified yesterday--you did testify yesterday about contamination by run. Do you recall that?

258 DR. GERDES:

Yes.

259 MR. CLARKE:

That run may actually be two separate runs, correct?

260 DR. GERDES:

Yes. It is by date, so everything that was done on a particular day is considered a run.

261 MR. CLARKE:

All right. Even though it may be two runs on that day; is that correct?

262 DR. GERDES:

In your definition, yeah.

263 MR. CLARKE:

Well, run was by your definition, correct?

264 DR. GERDES:

Yes.

265 MR. CLARKE:

Is the chart then inaccurate by using the term "Run" as you have described it?

266 DR. GERDES:

No, I don't believe so. I mean, there is very rare if I can look through this.

267 (Brief pause.)
268 (Discussion held off the record between the Deputy District Attorneys.)
269 DR. GERDES:

On a quick look through here I don't see a single day where both analysts ran on the same day.

270 MR. CLARKE:

Okay. At this point it is your testimony from your review of your material briefly that you don't believe there was more than one run by two different analysts on the same day?

271 DR. GERDES:

On a quick read-through of the table I believe that is the case.

272 MR. CLARKE:

Okay. If in fact there were two runs by an analyst, that is by two analysts, two different analysts on the same day, wouldn't your charts about contamination by runs be wrong?

273 DR. GERDES:

No.

274 MR. CLARKE:

Even though they are two separate runs?

275 DR. GERDES:

The point really is you are getting confused in terms of--you are making too big a deal out of this "Run" definition. The point behind this is to look at time, what happened on a given day, what is in that lab on that given day, what is in the lab the next day, what is in the lab across time over the course of a month. And so that is the thing that is really critical here in terms of what kind of contamination is occurring on different days.

276 MR. CLARKE:

You've already described on those charts contamination by strips. Do you recall that?

277 DR. GERDES:

Yes.

278 MR. CLARKE:

That is by individual strips; not by runs, correct?

279 DR. GERDES:

That's correct.

280 MR. CLARKE:

That is something different than contamination by runs, correct?

281 DR. GERDES:

Well, I believe I told--I titled it contamination and artifact by strip and that tells you how often--that gives you an idea or a sense of how often you see additional dots indicating additional human DNA in terms of just looking at every every step and asking that simple question. Is there a dot there that shouldn't be there?

282 MR. CLARKE:

Dr. Gerdes, if your definition is a run is a run done by a single analyst and two different analysts perform runs on the same day and you treat that as one run, doesn't that make your chart wrong?

283 DR. GERDES:

It may be wrong by one item in the--in that particular entry. I don't believe so. I just checked through here and I don't think there this is a date where a single--you know, two analysts ran on the same day.

284 MR. CLARKE:

So it is your view that it may be wrong by one, but that is okay?

285 DR. GERDES:

No. It is my view that I went through here and I don't believe that there is an error and that a run has more to do--you are confusing it. It has more to do with what is going on at a particular time.

286 MR. CLARKE:

Now, as far as--and this chart you created, the several-page document that you described earlier, you originally constructed that document and named it, correct?

287 DR. GERDES:

Yes.

288 MR. CLARKE:

The original name of that document was what, the chart I'm referring to that you've constructed that is several eight-and-a-half-by-eleven pages?

289 DR. GERDES:

I believe it was the observation of--something to the effect of LAPD DQ-Alpha contamination. I believe that is--something to that effect. I don't have the original chart with me.

290 MR. CLARKE:

All right. Would it be consistent--perhaps if I could refresh your recollection. Would it refresh your recollection to see a copy of that original chart?

291 DR. GERDES:

That's fine.

292 MR. CLARKE:

With the Court's permission.

293 (Brief pause.)
294 MR. CLARKE:

Showing you my copy, Dr. Gerdes, does that refresh your recollection as to your original name for your chart?

295 DR. GERDES:

Yes, "LAPD contamination incidents."

296 MR. CLARKE:

Actually that is not--

297 DR. GERDES:

During validation, 5/25/93 to 8/25/94.

298 MR. CLARKE:

I don't think you still get--

299 DR. GERDES:

"LAPD DQ-Alpha contamination incidents."

300 MR. CLARKE:

Did you ever change the title of that chart?

301 DR. GERDES:

It was--basically that is--I was interested in looking for those--

302 MR. CLARKE:

I'm sorry. Dr. Gerdes, did you ever change the name of the chart?

303 DR. GERDES:

Yes.

304 MR. CLARKE:

And you renamed it?

305 DR. GERDES:

Yes.

306 MR. CLARKE:

First of all, the first chart, to your knowledge was that provided to the People of this case?

307 DR. GERDES:

Yes.

308 MR. CLARKE:

When did that occur, approximately, to your knowledge?

309 DR. GERDES:

January.

310 MR. CLARKE:

Is it your testimony--well, when did you construct that chart?

311 DR. GERDES:

Well, it was constructed over the course of many months.

312 (Discussion held off the record between the Deputy District Attorneys.)
313 DR. GERDES:

It was never finalized until just recently when I changed the title. It was constructed over a period of many months.

314 MR. CLARKE:

You completed that chart in January of this year?

315 DR. GERDES:

No. I said it was constructed over many months.

316 MR. CLARKE:

When you said January, what did you mean?

317 DR. GERDES:

I--I don't remember exactly when I mailed my first copy of that, but I believe it was around January.

318 MR. CLARKE:

Mailed your first copy to who?

319 DR. GERDES:

To the Defense.

320 MR. CLARKE:

In this case?

321 DR. GERDES:

Yes, but at that point it was--it was a working document and it hasn't been--it wasn't finalized until just recently.

322 MR. CLARKE:

What do you mean "A working document"?

323 DR. GERDES:

Well, as you can see there are a thousand strips I was looking through. I wanted to double-check things. I went through it a number of times. I changed the title. I changed entries. These are things I'm working on.

324 MR. CLARKE:

You looked at that closely to make sure that that document was accurate, didn't you?

325 DR. GERDES:

To the best of my ability, yes.

326 MR. CLARKE:

You did everything you could to make sure you made no mistakes in that document; isn't that correct?

327 DR. GERDES:

That's correct.

328 MR. CLARKE:

In fact if that was a working document in January of 1995, if that document was not provided to the People until a later time, you wanted to make sure that that document was a hundred percent accurate?

329 DR. GERDES:

To the best of my ability.

330 MR. CLARKE:

When did you change the name of that chart?

331 DR. GERDES:

Umm, it was in early June, I believe. I'm not sure what the date was exactly. Well, the report--I don't have a copy of the letter, but it was not that long ago, within a month.

332 MR. CLARKE:

Okay. Let's go back for a moment if we can. You say this is a working document and you were making changes to it. What changes were you making from January and over the months since January?

333 DR. GERDES:

The way I constructed that chart was to go through and make the entries and then I would double-check them and I would also--I would--as I went through the first run through I would have questions, you know, have--have them see if they can get another copy of this strip or this one is missing, for instance, the initial discovery that we received was incomplete. We had to have--we had to go back to the laboratory actually in January and get a second set, a totally different set of photographs for strips that were missing. So once I had strips coming in that were missing, I would go ahead and revise the table with regards to strips that were provided later, that sort of thing.

334 MR. CLARKE:

Is it your testimony that all you did after January was add notations with strips you hadn't seen yet?

335 DR. GERDES:

For the most part, yes.

336 MR. CLARKE:

Were there other changes to the chart?

337 DR. GERDES:

There is one change, yes, or actually a couple of changes.

338 MR. CLARKE:

All right. We will return to those, but as far as this working document and other than the strips that you were given that you didn't have and the changes we will discuss, did you make any other changes to that document between January of this year and June 1st of this year?

339 DR. GERDES:

Yes.

340 MR. CLARKE:

What were those changes? What types of changes?

341 DR. GERDES:

Again, when I go through the first time I would make notations, look at this strip. It was a working document. I would go back and as I--I have convinced myself on certain strips, I would either decide not to call that one or to call that one or to try and get a better photograph, double-check, make sure that everything is accurate.

342 MR. CLARKE:

During this process did you discuss these individual strips with anyone?

343 DR. GERDES:

No.

344 MR. CLARKE:

You discussed them with no one for the Defense?

345 DR. GERDES:

I discussed the fact I was doing this. I was looking at them.

346 MR. CLARKE:

I'm talking about just results in an individual strip, let's say.

347 DR. GERDES:

Not on an individual strip basis, no.

348 MR. CLARKE:

Did you discuss any of them with Dr. Blake?

349 DR. GERDES:

No.

350 MR. CLARKE:

To your knowledge Dr. Blake observed typing in this case, correct?

351 DR. GERDES:

He took photographs of the typing at DOJ and he observed that typing being done, I believe. I'm not sure.

352 MR. CLARKE:

You discussed none of the interpretations that you made of the LAPD results with him; is that right?

353 DR. GERDES:

These of my interpretations? No.

354 MR. CLARKE:

Are these your interpretations only?

355 DR. GERDES:

Yes.

356 MR. CLARKE:

No, you renamed the chart, correct? We discussed that?

357 DR. GERDES:

Yes.

358 MR. CLARKE:

What did you rename the chart, and if it would refresh your recollection to look at the new chart--

359 DR. GERDES:

I've got it here.

360 MR. CLARKE:

All right.

361 DR. GERDES:

"LAPD DQ-Alpha unexpected alleles during validation 5/25/93 to 8/25/94."

362 MR. CLARKE:

So you made the decision to change the title "Contamination incident" and change those two words of the title to "Unexpected alleles"; is that correct?

KEY QUOTE
363 DR. GERDES:

Yes.

364 MR. CLARKE:

That was to make your chart more accurate, correct?

365 DR. GERDES:

That's correct.

366 MR. CLARKE:

And that is because there may not be contamination in many of the instances that you describe in this chart, correct?

367 DR. GERDES:

Well, I believe I described it yesterday. It is--the first step is to just ask the simple question is there a dot there that shouldn't be there?

368 MR. CLARKE:

I'm sorry, your Honor. Objection, nonresponsive.

369 THE COURT:

Overruled.

370 DR. GERDES:

The second step is to interpret those strips in the context of a given day to see if that can be confirmed as contamination.

371 THE COURT:

Ask your question again.

372 MR. CLARKE:

Surely.

373 MR. CLARKE:

Dr. Gerdes, you renamed that chart from "Contamination incidents" to "Unexpected alleles" because there are many instances in your chart that may not be contamination, correct?

374 DR. GERDES:

I don't believe there are many.

375 MR. CLARKE:

How many do you think there are?

376 DR. GERDES:

Specifically on the 1.1 allele where the question would arise, 7.6 percent of those 1.1 alleles could be interpreted as DX. Specifically in terms of the 1.3 allele, which is the other allele where it is known to have cross-hybridization, approximately 25 percent of those might be explained by that cross-hybridization. On all of the other alleles the 4, 2, 3, 1.2, that--those specific alleles have never been described to have those kind of problems, so they stand as real contaminants.

377 MR. CLARKE:

Dr. Gerdes, as you sit here today, is it your testimony that other than that 7.6 percent regarding the DX 1.1 allele that all of the remaining incidents, strip by strip incidents that you note in your chart, are contamination period?

378 DR. GERDES:

That--that is--it is consistent with that, yes.

379 MR. CLARKE:

That is not what I'm asking, doctor. Are they contamination or not?

380 DR. GERDES:

It depends on the allele. You have to look at it allele by allele. We already discussed the fact that there is an ambiguity if you have a 1.1 and a 1 dot. Now you can't decide. Now, I chose to count--since you can't decide if it is a contaminant or not in this analysis, I chose to count that as a contaminant. You can argue in fact, and you have that that 1.--that particular allele, the 1.1, even those might be ambiguous, they might be DX and that--that is true, but other than those, all of the rest are contamination.

381 MR. CLARKE:

In other words, other than the 7.6 percent--and those are the percentages that relate to your interpretations in DX, correct?

382 DR. GERDES:

Correct.

383 MR. CLARKE:

Other than those, it is your testimony today that all of the remaining incidents that you identify in your chart are contamination?

384 MR. SCHECK:

Objection, misstates the testimony.

385 THE COURT:

Overruled.

386 DR. GERDES:

Again, the 1.3 allele, you analyze that the same way on the 1.3 allele. If you have a 1 dot as well as the 1.3, you can't tell if that is cross-hybridization. If you have the 1.3 only, that could be considered cross-hybridization, so that is 25 percent where the 1.3 dot only showed up and not the 1 dot, so those also are in question. But with the exception of those two, all of the rest are defined as contamination.

387 MR. CLARKE:

So Dr. Gerdes, 7.6 percent relates to DX activity that it may be, correct?

388 DR. GERDES:

7.6 percent of the 1.1 alleles.

389 MR. CLARKE:

Is it your testimony that with the exception of those, all the rest of the incidents that you have charted are contamination?

390 MR. SCHECK:

Objection, misstates the testimony. Asked and answered.

391 THE COURT:

Sustained.

392 MR. CLARKE:

When you renamed this chart you eliminated the word "Contamination," correct?

393 DR. GERDES:

Yes.

394 MR. CLARKE:

You have described in your review the fact that you looked at photographs of these strips at the LAPD in January, was it, 1995?

395 DR. GERDES:

Yes.

396 MR. CLARKE:

Did you conduct a review at that laboratory, that is, in person at the laboratory, on any other date of these strips?

397 DR. GERDES:

I believe so. In December we looked at some, too.

398 MR. CLARKE:

So to your recollection you visited the lab twice?

399 DR. GERDES:

Yes.

400 MR. CLARKE:

It involved examining these various strips?

401 DR. GERDES:

That's correct.

402 MR. CLARKE:

You also described the fact that photographs were taken of the photographs of the strips in their book?

403 DR. GERDES:

That is on the second occasion, yes.

404 MR. CLARKE:

All right. Were those photographs of all of the strips or just ones that you had some concern about getting a photograph of?

405 DR. GERDES:

They were a subset--initially photographs were provided by LAPD and on the second visit in January we photographed strips that were missing or those that I wanted to see and have rephotographed because their photographs was not of good quality.

406 MR. CLARKE:

When you say "Their photographs," whose do you mean?

407 DR. GERDES:

LAPD.

408 MR. CLARKE:

You then wanted to ensure you had a photograph of each of the 1 through 261 other than the polymarkers that you didn't review?

409 DR. GERDES:

Correct.

410 MR. CLARKE:

Did you then obtain a photograph of each of the strips that involve again this DQ-Alpha typing process?

411 DR. GERDES:

Yes.

412 MR. CLARKE:

Now, in this--at the time you renamed the chart, to your knowledge was that provided to the People as well, the renamed chart?

413 DR. GERDES:

I believe it was, yes.

414 MR. CLARKE:

To your knowledge was a document also provided to the People indicating your discovery of errors in your chart?

415 DR. GERDES:

Yes.

416 MR. CLARKE:

And in particular, as part of your review of your chart, you discovered two errors that you had made, correct?

417 DR. GERDES:

They are not really errors. They are recalls or reconsiderations in terms of what I would characterize those specific samples.

418 MR. CLARKE:

Well, in one of those instances you labeled a standard as no. 1 and being a mistyping by the LAPD, correct?

419 DR. GERDES:

I never recorded it as that. If you look at the original table--table, it was recorded as "Standard one question, question mark, typed as `check this.'"

420 MR. CLARKE:

From your original review, and your initial chart provided to the People, you described six mistyping errors by the LAPD, correct?

421 DR. GERDES:

Correct.

422 MR. CLARKE:

When you reviewed your material and renamed and corrected your chart, you described five errors by the LAPD; is that right?

423 DR. GERDES:

That's right.

424 MR. CLARKE:

The error rate that you originally described in your first chart was incorrect; is that right?

425 DR. GERDES:

Not--it is still not--it is not incorrect. It basically--on that particular strip there--if you read the result--excuse me--the result, it is a mistyping.

426 MR. CLARKE:

Dr. Gerdes--

427 DR. GERDES:

But--

428 MR. CLARKE:

I'm sorry.

429 DR. GERDES:

If I can explain it, there is no C dot. There is a recording on the list from the analyst that says "No C dot." I felt I could see a C dot. If there is a C dot there, that is an error because it is a typeable result and it is an error, they recorded the incorrect type. But because the analyst wrote down "No C dot," I decided to change that and say that was not an error. In my opinion it is still an error, but I decided to change that because of the fact that I knew there would be an argument about whether or not the C dot was there and the fact that the analyst recorded there was no C dot; therefore, the analyst probably would not have considered that as a typeable result and would not have reported a typeable result that was an error. But in fact I feel I can see a C dot on that strip, and if there is a C dot there it is an error. If there isn't a C dot there, it is not an error.

430 MR. CLARKE:

So Dr. Gerdes, in your first chart you recorded it as an error? In your renamed altered chart you recorded it is as not an error, but your testimony is it is still an error? Is that fair?

431 DR. GERDES:

It is a little confusing, isn't it? I guess, yes, that is fair.

KEY QUOTE
432 MR. CLARKE:

As far as your chart, can you tell us how many actual records there are, hybridization records, the one page that may list eight samples or up to eight samples that you actually listed on your chart, and approximate number is fine?

433 DR. GERDES:

I think there is somewhere around 170, between 170, 180.

434 MR. CLARKE:

Okay. You are actually referring to something different, aren't you? I'm asking how many hybridization records, how many different single pages with up to eight samples on the page?

435 DR. GERDES:

Oh, this? 200--well, somewhere around 200 probably. I don't know exactly how many.

436 MR. CLARKE:

Okay. In reality there is only about eighty recorded on your chart, right?

437 DR. GERDES:

You are asking how many specific pages there are with strips on them? I haven't counted those so I don't know.

438 MR. CLARKE:

Okay. Can you tell us approximately, without counting them?

439 DR. GERDES:

You know, they are numbered from 1 to 201 and some of them the hybridization names are recorded on more than one page, so it is hard for me to estimate unless I count these.

440 MR. CLARKE:

Okay. You looked at--when you use 1 to 201, you mean 1 to 261?

441 DR. GERDES:

1 to 261 are the hybridizations. I just misread that. Sorry.

442 MR. CLARKE:

Okay. And you only recorded, as far as a record, a hybridization record, where you thought that something was a 1.1, correct, as far as those samples?

443 DR. GERDES:

On my table that is all I record.

444 MR. CLARKE:

The number of strips you examined was over 1000, correct?

445 DR. GERDES:

Correct.

446 MR. CLARKE:

Of the samples not recorded by you on your chart, is it your opinion there was no contamination revealed whatsoever?

447 DR. GERDES:

There was who contamination I could see on those.

448 MR. CLARKE:

What you did was record on your chart the occurrence of additional potential contaminant alleles, correct?

449 DR. GERDES:

Correct.

450 MR. CLARKE:

And in fact you used that exact language in your report, correct?

451 DR. GERDES:

Correct.

452 MR. CLARKE:

These are additional potential contaminant alleles, not contamination for sure, correct?

453 DR. GERDES:

Not unless you do the analysis on a per day basis.

454 MR. CLARKE:

Incidentally, this typing process included work done by analysts unrelated to this case, correct?

455 DR. GERDES:

Yes.

456 MR. CLARKE:

In other words, your survey was of every analyst who conducted typing in the Los Angeles Police Department during that time period?

457 DR. GERDES:

Yeah. What you want to do is look at the contamination--it is lab-related.

458 MR. CLARKE:

Sorry, objection, nonresponsive.

459 THE COURT:

Sustained. The answer is stricken. Reask the question.

460 MR. CLARKE:

Dr. Gerdes, did your review include work done by any analyst in the LAPD laboratory, whether connected to this case or not?

461 DR. GERDES:

Yes.

462 MR. CLARKE:

Incidentally, the polymarker results, they have controls as well on them, don't they?

463 DR. GERDES:

The polymarker has an s dot for determining the amount. The difficulty with the polymarker system is most of those are only two allele systems, so you don't have the luxury of looking for more than--I mean, there is only two there, so you can't look for more than two, so the same kind of analysis is more difficult.

464 MR. CLARKE:

Well, the--

465 DR. GERDES:

With the exception of two genes that are on there that have the three A, B, C genes.

466 MR. CLARKE:

Is there a reagent control on the polymarker strips?

467 DR. GERDES:

That is true, you can look at those.

468 MR. CLARKE:

Is there an amplification control on the polymarker strips?

469 DR. GERDES:

Yes.

470 MR. CLARKE:

In fact they are the same controls that are on the DQ-Alpha strips?

471 DR. GERDES:

Correct.

472 MR. CLARKE:

In fact, those controls can be looked at to show if they reveal contamination, can't they?

473 DR. GERDES:

They can be.

474 MR. CLARKE:

Wouldn't it be scientifically appropriate to look at the polymarker results as well if you are trying to find out how much contamination is in that laboratory?

475 DR. GERDES:

I would have if I had time. It is too long a time to do this.

476 MR. CLARKE:

So you felt you didn't have sufficient time to look at the entire records of the LAPD DNA typing laboratory?

477 DR. GERDES:

I felt that the DQ-Alpha--and I looked at spot checks on some of those and there were some of the same kind of things, and I did not have time to do a detailed analysis on the polymarker.

478 MR. CLARKE:

Wouldn't it be scientifically proper or wouldn't it be more appropriate to look at all of those 261 records instead of something over 200 of them?

479 DR. GERDES:

Well, the polymarker is not--they don't have normally as many strips on those either and it wasn't started until just more recently.

480 MR. CLARKE:

I'm sorry?

481 DR. GERDES:

They didn't start the polymarker until more recently.

482 MR. CLARKE:

Well, when did they start it, and I'm referring to even their validation studies?

483 DR. GERDES:

I don't have that record with me right now.

484 MR. CLARKE:

Okay.

485 DR. GERDES:

It was later--I hate to guess. I don't remember when.

486 MR. CLARKE:

It was before June of 1994, wasn't it?

487 DR. GERDES:

I believe it was.

488 MR. CLARKE:

And didn't it cover the time period of, let's say, May, June and July, 1994?

489 DR. GERDES:

I would have to look at the record to see if they did any polymarkers in that time frame. I don't remember them doing a lot in that time period.

490 MR. CLARKE:

They certainly started doing it before May of 1994, didn't they?

491 DR. GERDES:

The casework.

492 MR. CLARKE:

No, the--

493 DR. GERDES:

Validation?

494 MR. CLARKE:

--same types of typing that you reviewed for DQ-Alpha?

495 DR. GERDES:

I believe they did.

496 (Discussion held off the record between the Deputy District Attorneys.)
497 MR. CLARKE:

Now, what I would like to address, Dr. Gerdes, in the remaining minutes that we have today--I'm sorry?

498 THE COURT:

5:00.

499 MR. CLARKE:

Very well.

500 MR. CLARKE:

The errors that you have described, and let's start, if we could, with the first error, and I'm going to refer to them chronologically if I can.

501 DR. GERDES:

Okay.

502 MR. CLARKE:

In other words, from earliest to latest.

503 DR. GERDES:

That's fine.

504 MR. CLARKE:

In chronological order if that is okay. Your first error identified relates to hybridization record no. 15; is that right?

505 DR. GERDES:

That's correct.

506 MR. CLARKE:

Could I have a moment, your Honor?

507 (Discussion held off the record between the Deputy District Attorneys.)
508 MR. CLARKE:

And do you have a record of that?

509 DR. GERDES:

I do.

510 MR. SCHECK:

Your Honor, we don't have duplicate sets. May I stand by the witness to look at them?

511 (Brief pause.)
512 (Discussion held off the record between the Deputy District Attorneys.)
513 MR. CLARKE:

Your Honor, I have a document that I would like to have marked as the People's next exhibit.

514 THE CLERK:

558.

515 THE COURT:

558.

516 MR. CLARKE:

558, which I will show to counsel.

517 (Brief pause.)
518 (Peo's 558 for id = photograph)
519 THE COURT:

Mr. Clarke.

520 MR. SCHECK:

Your Honor, we want to compare the pictures because they are two different generations of photographs.

521 (Brief pause.)
522 DR. GERDES:

Okay.

523 MR. CLARKE:

I'm sorry, People's exhibit 558?

524 THE COURT:

558.

525 MR. CLARKE:

Does that appear to be a photograph of--not just the photograph of that particular hybridization set of strips, but also of the actual page itself, the document?

526 DR. GERDES:

Yes, it does.

527 MR. CLARKE:

And does it appear to be an accurate reproduction and contain the same documentary information as what you have in your own notebook?

528 DR. GERDES:

Yes.

529 MR. CLARKE:

As far as the photograph is concerned, does it appear to be approximately the same--the same as the photograph that you have?

530 DR. GERDES:

Yes. I mean, I have a Xerox here on mine at the moment, so--which is bothering me, but that seems to be the case.

531 MR. CLARKE:

If you don't have a photograph, then what I can simply ask you to do is to look at this original on the elmo, with the Court's permission?

532 DR. GERDES:

Okay. Okay. It appears--this is--

533 THE COURT:

All right.

534 DR. GERDES:

Yeah.

535 MR. CLARKE:

Your Honor, with the Court's permission then what I would ask to do is to place People's 558 on the elmo.

536 MR. CLARKE:

Now, I don't intend to ask Dr. Gerdes about dots and intensities, and perhaps if there is anytime you feel it is important to look at them, please tell me for purposes of this questioning.

537 DR. GERDES:

Okay, okay.

538 MR. CLARKE:

You have documented in your analysis one of the samples in this particular run as being one of the five errors that you testified to yesterday, correct?

539 DR. GERDES:

That's correct.

540 MR. CLARKE:

And, first of all, just a little bit about this record. This is a run that occurred on what date?

541 DR. GERDES:

On 7/14/93.

542 MR. CLARKE:

And that is reflected at the top of the hybridization record?

543 DR. GERDES:

That's correct.

544 MR. CLARKE:

And the analyst is also identified on the record, correct?

545 DR. GERDES:

Yes.

546 MR. CLARKE:

And the analyst is whom?

547 DR. GERDES:

In this particular case it is Erin Riley.

548 MR. CLARKE:

And then there is also information about confirming analyst; is that right?

549 DR. GERDES:

Yes.

550 MR. CLARKE:

What is a confirming analyst?

551 DR. GERDES:

A second person who looks at the typing and basically confirms it.

552 MR. CLARKE:

So someone who didn't actually perform the actual bench work but rather is asked to come in and look at the strip results?

553 DR. GERDES:

Yes.

554 MR. CLARKE:

And either concur or disagree with the analyst him or herself?

555 DR. GERDES:

That's correct.

556 MR. CLARKE:

And the confirming analyst in this run was whom?

557 DR. GERDES:

Collin Yamauchi.

558 MR. CLARKE:

Now, this particular run on 7/14 of `93 was about eleven months before the incident in question in this case?

559 DR. GERDES:

That's correct.

560 MR. CLARKE:

And would this then be during the fairly early stages of the LAPD's use of DNA typing?

561 DR. GERDES:

They began in May, so that is fair to say, yes.

562 MR. CLARKE:

Now, in particular, the error you identified--and I'm going to ask if we can zoom in on the first row not of the photograph but of the actual written documentation. Actually, if we can go up and zoom out a little bit. Perhaps just a little bit more. Perfect.

563 MR. CLARKE:

The error that you identified is actually on the first sample listed on the chart which is labeled on the left no. 1, correct?

564 DR. GERDES:

That's correct.

565 MR. CLARKE:

Which has identifying information and then a description of the medical sign for female reference blood?

566 DR. GERDES:

Correct.

567 MR. CLARKE:

And the results of that test by Erin Riley she has written down on the far right "1.3, 4," correct?

568 DR. GERDES:

Correct.

569 MR. CLARKE:

Now, in the course of that run there was activity in one of the negative controls; is that right?

570 DR. GERDES:

Yes.

571 MR. CLARKE:

And in fact written down, and perhaps we can zoom in a little bit on the very lower right-hand corner of the eight-segment graph--

572 (Discussion held off the record between the Deputy District Attorneys.)
573 MR. CLARKE:

Can you read that from there, Dr. Gerdes?

574 DR. GERDES:

Maybe it would be better if I stepped down if that is --

575 MR. CLARKE:

Okay.

576 DR. GERDES:

Okay. "1.2, 4, no C."

577 MR. CLARKE:

Actually it is noted "W" for "Weak"; is that right?

578 DR. GERDES:

Yes.

579 MR. CLARKE:

"1.2, 4"?

580 DR. GERDES:

Correct.

581 MR. CLARKE:

And then in parenthesis "No c"?

582 DR. GERDES:

That's correct, on the cloth control, the substrate control, the extraction control.

583 MR. CLARKE:

Actually that is not a substrate control?

584 DR. GERDES:

That is why I corrected myself; an extraction control.

585 MR. CLARKE:

That is a control you described earlier that in the course of typing that is supposed to be negative, correct?

586 DR. GERDES:

That's right, so this is definite contamination.

587 MR. CLARKE:

Objection. Move to strike, your Honor, nonresponsive.

588 THE COURT:

Sustained, stricken.

589 MR. CLARKE:

As far as that control is concerned, if that is not negative, the result shouldn't be reported, correct?

590 DR. GERDES:

That's correct.

591 MR. CLARKE:

And in fact the 1.3, 4 shouldn't be reported because of that activity?

592 DR. GERDES:

That's correct.

593 MR. CLARKE:

Was this result ever reported in a report somewhere?

594 DR. GERDES:

No.

595 MR. CLARKE:

The only showing of those alleles that is the call on that reference blood, is the 1.3, 4 that is written under dq-A1 results, correct?

596 DR. GERDES:

That's correct.

597 MR. CLARKE:

Erin Riley was the analyst, correct?

598 DR. GERDES:

Correct.

599 MR. CLARKE:

As result of the activity in the negative control didn't she rerun this sample?

600 DR. GERDES:

I'm not sure if that is the reason she did it. I don't know why she did it, but she did rerun the sample.

601 MR. CLARKE:

Wouldn't it be scientifically appropriate to rerun that sample because of the control that showed activity?

602 DR. GERDES:

It would be scientifically acceptable to begin with something that hadn't even been exposed to that laboratory and rerun it.

603 MR. CLARKE:

Well, let's--

604 DR. GERDES:

I mean we have a contamination problem here.

605 MR. CLARKE:

Objection, move to strike, your Honor.

606 THE COURT:

Sustained. The answer is stricken.

607 MR. CLARKE:

Dr. Gerdes, that 1.3, 4 that is written in by Erin Riley, that is not the correct type for that sample, right?

608 DR. GERDES:

That's correct.

609 MR. CLARKE:

And in fact that sample is actually a 1.2, 4?

610 DR. GERDES:

That's correct.

611 MR. CLARKE:

When Erin Riley reran that sample, if she reran that sample, that was the proper thing to do, wasn't it?

612 DR. GERDES:

To rerun it, yes.

613 MR. CLARKE:

She in fact did rerun that sample, didn't she?

614 DR. GERDES:

Yes.

615 MR. CLARKE:

All right. Your Honor, I have a second similar photograph I would ask be marked People's 559.

616 THE COURT:

So marked.

617 (Peo's 559 for id = photograph)
618 MR. CLARKE:

May I approach the witness, your Honor?

619 THE COURT:

You may.

620 MR. CLARKE:

Dr. Gerdes, showing you what is labeled at the top "Hybridization 19," is that a similar photograph of a hybridization record and photograph attached to that record as was the case with the previous exhibit that we've discussed?

621 DR. GERDES:

Yes, it is.

622 MR. CLARKE:

And does it appear--contain the same information that you have in your own records?

623 DR. GERDES:

Yes.

624 MR. CLARKE:

All right. With the Court's permission I would like to also place that on the elmo.

625 THE COURT:

Doctor, do you have your copy of that?

626 DR. GERDES:

I don't have the photo, but I have this--the sheet.

627 MR. CLARKE:

Actually just to be clear, Dr. Gerdes, that previous photo, exhibit 558, Erin Riley called the dots, the probes, the alleles, that she observed in that typing strip, correct?

628 DR. GERDES:

Yes.

629 MR. CLARKE:

And as far as her noting the 1.3 allele and the 4 allele, your review also revealed that the 1.3 allele and the 4 allele were present, correct?

630 DR. GERDES:

Correct.

631 MR. CLARKE:

So as far as what she noted seeing on that strip, you agree with what she noted?

632 DR. GERDES:

That's true, I do.

633 MR. CLARKE:

Now, looking at the next exhibit, 559, and if we can zoom in on the same area, let's start there. This is a similar record, correct?

634 DR. GERDES:

Yes.

635 MR. CLARKE:

And in fact on this record--your Honor, I have skipped one exhibit. I'm going to have to ask that another one be marked as what would be People's 560.

636 THE COURT:

560.

637 MR. CLARKE:

We will do that in chronological order.

638 THE COURT:

Do you want to substitute that for 559?

639 MR. CLARKE:

No, we will also use it.

640 (Peo's 560 for id = photograph)
641 (Brief pause.)
642 (Discussion held off the record between Deputy District Attorney and Defense counsel.)
643 MR. CLARKE:

No, we will also use it.

644 THE COURT:

All right.

645 (Brief pause.)
646 (Discussion held off the record between Deputy District Attorney and Defense counsel.)
647 THE COURT:

Why don't you show that to Dr. Gerdes so he can find his copy.

648 MR. CLARKE:

Yes. Dr. Gerdes, showing you, if I can, what will be People's exhibit 560, does that appear to be a similar photograph of a record and photo?

649 DR. GERDES:

Yes.

650 MR. CLARKE:

And do you have a Xerox of that?

651 DR. GERDES:

I have a photo of that one.

652 MR. CLARKE:

All right. With the Court's permission may I place 560 on the elmo?

653 THE COURT:

Yes.

654 (Brief pause.)
655 MR. CLARKE:

Now, as far as this particular record, which is People's 560, does that appear to be a record from the next day, July 15th, `93?

656 DR. GERDES:

That's correct.

657 MR. CLARKE:

And the analyst is again Erin Riley?

658 DR. GERDES:

That's correct.

659 MR. CLARKE:

And the confirming analyst is Collin Yamauchi?

660 DR. GERDES:

That's correct.

661 MR. CLARKE:

And was that same sample run on that day also?

662 DR. GERDES:

It was.

663 MR. CLARKE:

Now, on this particular set of hybridization records what location was that sample that was rerun from the previous day?

664 DR. GERDES:

In terms of--

665 MR. CLARKE:

One that was called an error by you? In other words, is that sample rerun on this exhibit?

666 DR. GERDES:

It is, yes.

667 MR. CLARKE:

560?

668 DR. GERDES:

Yes.

669 MR. CLARKE:

And as far as the numbers 1 through 8 on the chart?

670 DR. GERDES:

Okay. It is no. 1.

671 MR. CLARKE:

Okay. Then if we could then zoom in on the no. 1 row. That is fine.

672 MR. CLARKE:

And that top row again constitutes the written record?

673 DR. GERDES:

Correct.

674 MR. CLARKE:

Of Erin Riley's rerun of the same victim reference blood?

675 DR. GERDES:

That's correct.

676 MR. CLARKE:

And on that occasion she noted the alleles 1.3 and 4 being present; is that right?

677 DR. GERDES:

That's correct.

678 MR. CLARKE:

And that notation is the first notation in the immediate--I'm sorry, the far right column that is labeled "Dq-A1 results," correct?

679 DR. GERDES:

Correct.

680 MR. CLARKE:

At the very bottom is another cloth control, correct?

681 DR. GERDES:

Correct.

682 MR. CLARKE:

That cloth control again showed activity, correct?

683 DR. GERDES:

That's correct.

684 MR. CLARKE:

And in fact what is noted for the activity seen by both Erin Riley and Collin Yamauchi with that negative control?

685 DR. GERDES:

The negative control contains 1.2, 1.3 allele.

686 MR. CLARKE:

In view of the existence of that activity in the negative control, isn't it scientifically proper to rerun that sample again?

687 DR. GERDES:

That would be what you would do, yes.

688 MR. CLARKE:

And in fact you called this an error again; isn't that right?

689 DR. GERDES:

It is an error in the sense that that contamination in the laboratory created a false typing result.

690 MR. CLARKE:

Is it your testimony that Erin Riley called that result?

691 DR. GERDES:

That result is recorded.

692 MR. CLARKE:

Is it your testimony that from this document Erin Riley conclusively established, for purposes of reporting results, that that was a 1.3, 4?

693 DR. GERDES:

No. My testimony is that that result was recorded as a type that was an incorrect type as a result of the contamination that was to found in the lab.

694 MR. CLARKE:

Wasn't Erin Riley--let me rephrase. Didn't she rerun this sample again because of that activity in the negative control?

695 DR. GERDES:

Yes.

696 MR. CLARKE:

Wasn't that the right thing to do scientifically?

697 DR. GERDES:

Yes.

698 MR. CLARKE:

And in fact did she rerun that sample as reflected in what is People's exhibit 559 which I showed to you a few moments ago?

699 DR. GERDES:

Yes.

700 (Discussion held off the record between the Deputy District Attorneys.)
701 MR. CLARKE:

Incidentally, before we do that, Dr. Gerdes, you are not faulting Erin Riley for noting the alleles that she saw in that sample, are you?

702 DR. GERDES:

No. I'm simply saying the contamination at the laboratory created this false--

703 MR. CLARKE:

I'm sorry, nonresponsive, your Honor.

704 THE COURT:

Sustained. Answer is stricken.

705 MR. CLARKE:

She did the right thing by rerunning that again, didn't she?

706 DR. GERDES:

That would be the thing to do.

707 MR. CLARKE:

All right. With the Court's permission I would like to again place on the elmo People's 559.

708 MR. CLARKE:

Now, lastly, Dr. Gerdes, with respect to this series of runs, this was a run conducted by Erin Riley on or two days later, July 17, `93, correct?

709 DR. GERDES:

Yes.

710 MR. CLARKE:

And she reran that same sample again, didn't she?

711 DR. GERDES:

Yes.

712 MR. CLARKE:

Now, on that chart, if we can focus in just on the graph portion of the chart, can you tell us, doctor, where that sample is on this chart?

713 DR. GERDES:

It is in lane 6.

714 MR. CLARKE:

Okay. Lane 6. That would be with the no. 6 off to the far left?

715 DR. GERDES:

Yes.

716 MR. CLARKE:

And then reading across to the right--this would be three rows from the bottom, correct?

717 DR. GERDES:

Correct.

718 MR. CLARKE:

And it is labeled on this particular record as FID, space, 01?

719 DR. GERDES:

Correct.

720 MR. CLARKE:

What is FID 01?

721 DR. GERDES:

Well, that stands--that is FID is an abbreviation that is used in the proficiency testing, so this is actually a proficiency test that they were sent a sample and that is just one of the labels for that sample.

722 MR. CLARKE:

All right. And over to the far right of that same sample and this has been run for the third time by Erin Riley, correct?

723 DR. GERDES:

Correct.

724 MR. CLARKE:

This notes the alleles 1.2, 4; is that right?

725 DR. GERDES:

That's correct.

726 MR. CLARKE:

That answer was correct, wasn't it?

727 DR. GERDES:

Yes.

728 MR. CLARKE:

Looking at the cloth control, the negative control, what activity did that negative control show?

729 DR. GERDES:

In this particular case there is no activity.

730 MR. CLARKE:

She noted no activity, correct?

731 DR. GERDES:

Correct.

732 MR. CLARKE:

Collin Yamauchi agreed there was no activity?

733 DR. GERDES:

Correct.

734 MR. CLARKE:

And you agreed there was no activity in your review of the photograph?

735 DR. GERDES:

Correct.

736 MR. CLARKE:

She got a correct answer when the controls operated properly, correct?

737 DR. GERDES:

Correct.

738 MR. CLARKE:

That correct answer is not noted in your chart, is it?

739 DR. GERDES:

My chart only records additional alleles. No, it is not.

740 MR. CLARKE:

Based on all of this information, Dr. Gerdes, is it your opinion that Erin Riley and the LAPD laboratory made two errors?

741 DR. GERDES:

The errors were caused by the contamination that was present in the laboratory.

742 MR. CLARKE:

Objection, nonresponsive. Move to strike, your Honor.

743 DR. GERDES:

Due to typing on the strip.

744 THE COURT:

Ask the question again.

745 MR. CLARKE:

Dr. Gerdes, is it your testimony that based on the first two runs before this one that those were two errors by Erin Riley?

746 DR. GERDES:

That were errors on that specific strip.

747 MR. CLARKE:

Incidentally, if such an incident occurred in your laboratory with activity showing in the negative controls, would you want your analyst to rerun that sample?

748 DR. GERDES:

Yes.

749 MR. CLARKE:

So Erin Riley did just what you would want her to do with these samples or this sample if she were working in your laboratory?

750 DR. GERDES:

That's correct.

751 MR. CLARKE:

Your Honor, I have another photograph I would ask be marked as People's 561.

752 THE COURT:

561.

753 (Peo's 561 for id = photograph)
754 MR. CLARKE:

Which I have shown to counsel. May I approach the witness, your Honor?

755 THE COURT:

You may.

756 MR. CLARKE:

Dr. Gerdes, showing you what is labeled "Hybridization no. 33," does that look familiar?

757 DR. GERDES:

Yes. Let me double-check it here.

758 (Brief pause.)
759 (Discussion held off the record between the Deputy District Attorneys.)
760 DR. GERDES:

Yes.

761 MR. CLARKE:

Now, this is another record that you reviewed?

762 DR. GERDES:

Yes.

763 MR. CLARKE:

And do you have a copy of that?

764 DR. GERDES:

I do.

765 MR. CLARKE:

All right. Your Honor, with the Court's permission I would like to place People's 561 on the elmo.

766 THE COURT:

Yes.

767 MR. CLARKE:

And if we can back out a little bit to see the whole page.

768 MR. CLARKE:

Now, Dr. Gerdes, this particular record relates to what date?

769 DR. GERDES:

September 9, 1993.

770 MR. CLARKE:

And that date again precedes the LAPD beginning casework, actually accepting cases in their DNA laboratory?

771 DR. GERDES:

Yes, yes.

772 MR. CLARKE:

Now, this particular run--actually this particular record involved the analyst--or involved Collin Yamauchi as the analyst, correct?

773 DR. GERDES:

That's correct.

774 MR. CLARKE:

So Collin Yamauchi actually performed the actual bench work?

775 DR. GERDES:

Correct.

776 MR. CLARKE:

And the confirming analyst was Erin Riley?

777 DR. GERDES:

Correct.

778 MR. CLARKE:

Now, in this particular sample, this reflects information from what you--from which you determined that there was a third error as far as mistyping in the DNA laboratory at the LAPD, correct?

779 DR. GERDES:

That's correct.

780 MR. CLARKE:

Now, the particular sample that you identified as being an error is which one on this particular record?

781 DR. GERDES:

It is the second strip down.

782 MR. CLARKE:

You are referring to on the actual graph with written information "Sample no. 2," which would be the second row down under "Description"?

783 DR. GERDES:

Correct. Let me see. Yes.

784 MR. CLARKE:

What type of sample was that?

785 DR. GERDES:

This is a sexual assault standard.

786 MR. CLARKE:

Okay. As far as this sample--this wasn't casework, correct?

787 DR. GERDES:

No.

788 MR. CLARKE:

Was this--

789 DR. GERDES:

It is a control.

790 MR. CLARKE:

I'm sorry?

791 DR. GERDES:

A control standard.

792 MR. CLARKE:

Well, wasn't this in fact one of a series of vaginal swabs that were tested using the DQ-Alpha system?

793 DR. GERDES:

Correct.

794 MR. CLARKE:

And a series of vaginal swabs that were tested basically as part of the validation process within the LAPD laboratory?

795 DR. GERDES:

Correct.

796 MR. CLARKE:

This process whereby analysts tested a number of different types of samples to ensure they were able to use the system properly?

797 DR. GERDES:

Correct.

798 MR. CLARKE:

Now, it is labeled--and let's start on the first sample because that will clarify what the second sample is, correct?

799 DR. GERDES:

Correct.

800 MR. CLARKE:

The first sample is labeled "No. 1 V." Does that stand for no. 1 victim?

801 DR. GERDES:

Yes.

802 MR. CLARKE:

And off to the right under "Description" is written "EC," right?

803 DR. GERDES:

Correct.

804 MR. CLARKE:

That that stands for what?

805 DR. GERDES:

Epithelial cell.

806 MR. CLARKE:

Okay. We will talk about that in a moment. Going now down to the sample that you have offered the opinion is an error, that relates to the same swab, correct?

807 DR. GERDES:

Correct.

808 MR. CLARKE:

And then as noted off to the right, "SC"?

809 DR. GERDES:

Correct.

810 MR. CLARKE:

Standing for what?

811 DR. GERDES:

Sperm cell.

812 MR. CLARKE:

Now, with regard to this particular sample, that is designed to be a vaginal swab for purposes of this test?

813 DR. GERDES:

Yes.

814 MR. CLARKE:

Containing what is labeled "EC" or cells from--

815 DR. GERDES:

The victim.

816 MR. CLARKE:

--the female as part of a sexual assault, correct?

817 DR. GERDES:

Correct.

818 MR. CLARKE:

And the actual sample that you have offered the opinion is an error, the SC sample, is supposed to be the sperm cells from the male who engaged in intercourse with this female; is that right?

819 DR. GERDES:

That's correct.

820 MR. CLARKE:

Now, the typing results obtained by Mr. Yamauchi as to the epithelial cell portion are 1.2, 4, in the far upper right-hand corner of the graph?

821 DR. GERDES:

That's correct.

822 MR. CLARKE:

And you agree with those results?

823 DR. GERDES:

Yes.

824 MR. CLARKE:

From your review of the photograph?

825 DR. GERDES:

Yes.

826 MR. CLARKE:

And in fact that properly shows what the DNA type is of the woman from whom that swab was taken, right?

827 DR. GERDES:

That's correct.

828 MR. CLARKE:

So that what the EC portion was showing was what was expected to be the portion from the person the swab was taken from, the woman?

829 DR. GERDES:

That's correct.

830 MR. CLARKE:

Now, relating to SC, that refers to male sperm; is that correct?

831 DR. GERDES:

Correct.

832 MR. CLARKE:

And in fact in this typing process that has been previously described in testimony in this case it is a feature of DNA that even though a sample in a sexual assault case may include DNA from the victim and DNA from, for instance, a rapist in a sexual assault crime, that DNA allows to a large extent separation of the female's DNA from the male's DNA; is that correct to say?

833 DR. GERDES:

By the process of a differential extraction there, without getting too deeply into that, that is a process by which the DNA analyst can break open just the victim's cells and hopefully not break open any of the sperm cells, right?

834 DR. GERDES:

Correct.

835 MR. CLARKE:

And then retrieve the victim's DNA and set it aside for typing, right?

836 DR. GERDES:

Correct.

837 MR. CLARKE:

And then go back and by some other chemical steps break open the sperm cells, set that aside and type that separately, right?

838 DR. GERDES:

That's correct.

839 MR. CLARKE:

This process--and you have used the term differential extraction, right?

840 DR. GERDES:

Yes.

841 MR. CLARKE:

That just describes this process of trying to separate these two types of cells?

842 DR. GERDES:

Correct.

843 MR. CLARKE:

That process is not perfect, is it?

844 DR. GERDES:

It is--it is not perfect in terms of the separation of the two always, correct.

845 MR. CLARKE:

And in fact in a sexual assault case it is not uncommon at all to find, for instance, in the epithelial cell portion some sperm DNA?

846 DR. GERDES:

That's correct.

847 MR. CLARKE:

Because during this process of breaking open the victim's cells some of the sperm may break open and release the DNA as well?

848 DR. GERDES:

That's correct.

849 MR. CLARKE:

And isn't it also correct that the opposite occurs, which is in breaking open the sperm cells some of the victim's cells didn't quite release the DNA in the first step and then they are left in the sperm fraction--I'm sorry, the sperm cell portion also?

850 DR. GERDES:

That is also correct.

851 MR. CLARKE:

Now, in this particular instance these results reflect the victim's DNA in both; is that right?

852 DR. GERDES:

That's correct.

853 MR. CLARKE:

In other words, the 1.2, 4 is consistent with the victim in the epithelial cell portion as well as the male sperm portion?

854 DR. GERDES:

That's correct.

855 MR. CLARKE:

That event, in the context of a mixed vaginal sexual assault sample, is not unexpected, is it?

856 DR. GERDES:

To find the epithelial alleles, no, that is not unexpected.

857 MR. CLARKE:

You called this an error, correct?

858 DR. GERDES:

That's correct.

859 MR. CLARKE:

And in fact a trained DNA analyst would not be surprised to find exactly what the results from Mr. Yamauchi revealed, correct?

860 DR. GERDES:

In terms of the epithelial fraction, that's true, but in terms of the sperm fraction that is not true.

861 MR. CLARKE:

Well, a trained analyst would look at those results and first of all, let's see, what is the type of the male donor of the sperm on that sample?

862 DR. GERDES:

The 1.2, 1.3.

863 MR. CLARKE:

All right. So there is one allele that is shared, the 1.2, right?

864 DR. GERDES:

Correct.

865 MR. CLARKE:

But the male's 1.3 isn't seen in either of these portions?

866 DR. GERDES:

That's correct. That is the error.

867 MR. CLARKE:

You have reviewed cases involving sexual assault samples as part of your work for criminal defendants, correct?

868 DR. GERDES:

I have.

869 MR. CLARKE:

And you have seen samples in which there are mixtures of victim's DNA in a vaginal swab along with a sexual assault or rapist's DNA, correct?

870 DR. GERDES:

Yes, I have.

871 MR. CLARKE:

And in fact you have seen samples in which the victim's DNA shows up in both portions, correct?

872 DR. GERDES:

Yes.

873 MR. CLARKE:

A trained analyst, an experienced analyst, even though seeing that 1.2, 4, in some of the cases that you've reviewed, would not exclude a person who is a 1.2, 1.3 from having, I'm sorry, contributed any DNA to that sample, correct?

874 DR. GERDES:

I don't believe that is correct.

875 MR. CLARKE:

Is it--

876 DR. GERDES:

I believe that they would.

877 MR. CLARKE:

Is it your view that a person can be excluded as a possible donor when their DNA just doesn't show up at all?

878 DR. GERDES:

You don't know. That is the problem. The 1.3 has been missed here. If this typing method is reliable, you can't miss things. If you miss things, how do you know that you didn't miss things on other samples? I mean, you can't do that.

879 MR. CLARKE:

Dr. Gerdes, with respect to a rapist, isn't it the case that in some cases they don't leave enough DNA?

880 DR. GERDES:

That is true, but in the case of a differential extraction the analyst is supposed to look at the specimen and observe sperm before they go ahead with the differential extraction, and if there is sperm there you should find the allele from the sperm and in this case that didn't happen.

881 MR. CLARKE:

Well, is it your testimony that a trained forensic DNA analyst would look at those results and conclude that the 1.2, 4, came from somebody other than the victim?

882 DR. GERDES:

They would most likely conclude that it came from the victim, the 1.2, 4.

883 MR. CLARKE:

And they wouldn't conclude that a person who is a 1.2, 1.3 couldn't have raped that person?

884 DR. GERDES:

If you had--I believe there would be an interpretation problem, but they would most likely not, you are right.

885 MR. CLARKE:

They would not exclude a 1.2, 1.3 from depositing DNA there, would they?

886 DR. GERDES:

And that is the problem. The person was a 1.2, 1.3, so it is an error that person would not have been--

887 MR. CLARKE:

Objection to strike, nonresponsive.

888 THE COURT:

Ask the question again.

889 MR. CLARKE:

Dr. Gerdes, a trained analyst would look at those results and they wouldn't exclude a 1.2, 1.3 as being a donor of sperm in that sample, would they?

890 DR. GERDES:

No, they wouldn't, and this person is a 1.2, 1.3. that is an error.

891 MR. CLARKE:

Dr. Gerdes, that is not an error at all, is it?

892 DR. GERDES:

There is an error. There is a 1.3 allele that you didn't find. That is significant.

893 MR. CLARKE:

Would somebody like Dr. Blake exclude a 1.2, 1.3 from that sample?

894 DR. GERDES:

I can't speak for Dr. Blake.

895 MR. CLARKE:

In your view are you as qualified as he to render opinions about matters like this involving sexual assault samples?

896 DR. GERDES:

Yes, I believe so.

897 MR. CLARKE:

Dr. Blake has had substantial casework experience, has he not?

898 MR. SCHECK:

Your Honor, I think this line is--

899 THE COURT:

Sustained.

900 MR. SCHECK:

Objection.

901 THE COURT:

Sustained.

902 MR. CLARKE:

Your Honor, I have one more record I would like to be marked as a People's exhibit.

903 THE COURT:

562, I believe.

Temperature

tense

Key Quotes (5)

Dr. John Gerdes
It is sort of like if you went into your house and you noticed a cockroach and then the next day you noticed another one, it would be an indication to you that maybe there are other roaches around and you maybe better do something about it.
Gerdes' colorful analogy for systemic lab contamination — memorable but also somewhat folksy for a supposedly rigorous scientific expert, which Clarke immediately highlighted with a dry 'The cockroach comparison?'
George Clarke
So you made the decision to change the title 'Contamination incident' and change those two words of the title to 'Unexpected alleles'; is that correct? That was to make your chart more accurate, correct? And that is because there may not be contamination in many of the instances that you describe in this chart, correct?
Clarke gets Gerdes to confirm that his headline contamination chart was renamed precisely because many entries may not be contamination at all — a devastating methodological concession.
Dr. John Gerdes
It is a little confusing, isn't it? I guess, yes, that is fair.
Gerdes admitting that his first chart called something an error, his revised chart called it not an error, but he still personally believes it is an error — a moment of visible discomfort that undermined his precision.
Dr. John Gerdes
In your view is it important to have experience in actually using a technique to be able to interpret it, as you have done in this case? No.
Clarke extracts the admission that Gerdes has never personally performed a forensic PCR DQ-Alpha analysis, yet claims to be able to critique the LAPD's results — a clean impeachment of his practical authority.
George Clarke
How many other laboratories have you examined all of their PCR DQ-Alpha typing strips for a 15-month time period? For that long a period, none — no other laboratory for that long.
Clarke establishes there is no comparative baseline for Gerdes' 'worst contamination I've ever seen' claim — the LAPD is the only lab Gerdes ever examined over such a long period, making the comparison meaningless.

Evidence (4)

People's 558
Document introduced near end of session, related to hybridization record no. 15 and the first LAPD typing error Gerdes identified
Introduced and marked
Informal
Gerdes' original chart titled 'LAPD DQ-Alpha contamination incidents during validation 5/25/93 to 8/25/94'
Discussed and compared to renamed version
Informal
Gerdes' renamed chart titled 'LAPD DQ-Alpha unexpected alleles during validation 5/25/93 to 8/25/94'
Discussed; Clarke used renaming to challenge scope of contamination claims
Informal
LAPD run books containing hybridization records 1–261 with strip photographs, typed results, analyst names, and lot numbers
Discussed as the basis for Gerdes' review

Notable Exchanges (4)

George ClarkeDr. John Gerdes
Clarke systematically walked Gerdes through the renaming of his chart from 'contamination incidents' to 'unexpected alleles,' getting Gerdes to confirm the change was made because many entries are ambiguous — including 7.6% of 1.1 alleles possibly attributable to the DX gene and ~25% of 1.3 alleles possibly attributable to cross-hybridization.
devastating
George ClarkeDr. John Gerdes
Clarke revealed that Gerdes had never spoken to Fung, Mazzola, Matheson, or any LAPD analyst about their evidence collection, never asked Yamauchi interpretive questions, and had never performed forensic PCR analysis himself — all while claiming to authoritatively critique 1,069 strips.
strategic
George ClarkeDr. John Gerdes
Clarke pressed Gerdes on his 'run' definition, showing that Gerdes counted same-day work by two analysts as one run, and that his contamination-by-run chart could therefore be inaccurate. Gerdes became defensive and told Clarke he was 'making too big a deal out of this run definition.'
heated
George ClarkeDr. John Gerdes
Clarke established that Gerdes reviewed no other laboratory's full 15-month strip record, making his 'worst contamination I've ever seen' characterization of LAPD based on an incomparable sample — no other lab had been reviewed at anywhere near the same depth.
revealing

Light Moments (1)

George Clarke
Gerdes compared lab contamination to discovering cockroaches in a house; Clarke responded dryly with just 'The cockroach comparison?' drawing implicit laughter from the courtroom.

Credibility Attacks (4)

⚔ Dr. John Gerdes
Bias / methodological incompleteness
Clarke established Gerdes never interviewed any LAPD analyst or evidence collector, reviewed no polymarker results, and performed no forensic DNA analysis himself — yet offered sweeping conclusions about LAPD's contamination being 'by far the worst' he'd seen.
⚔ Dr. John Gerdes
Prior inconsistent document / document alteration
Clarke showed Gerdes changed his chart title from 'contamination incidents' to 'unexpected alleles' and reduced his reported LAPD mistyping errors from six to five, while Gerdes simultaneously testified he still personally believes the removed item was an error — suggesting post-hoc softening of his conclusions.
⚔ Dr. John Gerdes
Lack of comparative baseline
Clarke demonstrated that LAPD is the only laboratory Gerdes ever examined over a 15-month, 1,000+ strip period — making his 'worst lab I've ever seen' characterization statistically unfounded as a comparison.
⚔ Dr. John Gerdes
Concession under cross that chart entries may not be contamination
Gerdes admitted that the alleles flagged in his chart include items attributable to DX gene activity and cross-hybridization rather than true contamination, and that he had renamed the chart specifically because 'contamination' was not always accurate.

Witness Demeanor

(Brief pause.) (Discussion held off the record between the Deputy District Attorneys.)
Gerdes becomes evasive and verbose under pressure, frequently prompting 'objection, nonresponsive' and being cut off mid-explanation
Gerdes self-corrects on hybridization number range (saying '201' then correcting to '261') and on the DOJ strip count
Gerdes audibly uncomfortable acknowledging the chart error/non-error contradiction: 'It is a little confusing, isn't it? I guess, yes, that is fair.'

Objections

7 objections (4 sustained, 3 overruled)
Proceeding 7933 • 903 utterances • Defense witness
Criminal Trial
Department 103
⚖️ Start
📂 AUG 3, 1995 📄 Cross-examination of Dr. John
AUG 3, 1995 KRT DvH TD